The Fellow on Call: The Heme/Onc Podcast Episode 123: AML Series, Pt 9 - Introduction to Allogeneic Transplant
9 snips
Dec 4, 2024 Dr. Amar Kelkar, an instructor at Harvard Medical School and specialist at Dana-Farber, joins for an enlightening dive into allogeneic transplants for AML. He unpacks key eligibility criteria for patients, stressing the importance of minimal residual disease status. The conversation also illuminates the critical role of HLA matching and donor selection factors. Additionally, Dr. Kelkar compares various stem cell sources, revealing unique insights about outcomes in haploidentical and cord blood transplants. His expert perspective makes this complex topic accessible.
AI Snips
Chapters
Transcript
Episode notes
Transplant Eligibility
- Consider disease-specific eligibility and overall health for transplant.
- Prioritize intermediate-risk and higher AML patients, considering factors like FLT3 and NPM1 mutations.
AML Risk Stratification
- The 2022 European Leukemia Network guidelines simplified AML risk categorization.
- All FLT3 ITD mutations, regardless of allelic ratio, are now classified as intermediate risk.
Assessing Transplant Candidacy
- Use the HCTCI/SOAR score to assess transplant eligibility, considering comorbidities.
- Caregiver availability and health literacy are crucial implicit factors.